Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75161
UPID:
NPHP4_HUMAN
Alternative names:
Nephroretinin
Alternative UPACC:
O75161; Q8IWC0
Background:
Nephrocystin-4, also known as Nephroretinin, plays a crucial role in the organization of apical junctions and the subapical actin network in multiciliated epithelial cells. It is part of a NPHP1-4-8 module essential for building functional cilia and is involved in several signaling pathways, including the down-regulation of the canonical Wnt pathway and the negative regulation of the hippo pathway.
Therapeutic significance:
Nephrocystin-4 is implicated in Nephronophthisis 4 and Senior-Loken syndrome 4, both of which are characterized by renal disease and, in the case of Senior-Loken syndrome, additional eye disease. Understanding the role of Nephrocystin-4 could open doors to potential therapeutic strategies for these conditions.